Cambridge, Massachusetts.And February 2, 2023 /PRNewswire/ — via Scientific, Inc.new Cambridge The technology and AI-driven company, is proud to announce the launch of Foundry, a multi-faceted accelerator platform focused on dramatically shortening the path to scientific breakthroughs.
A new Cambridge-based analytics company has launched via Scientific, a leading multi-omics analytics platform.
The Foundry platform was originally developed at the UMass Chan School of Medicine; Via Scientific has exclusive commercial rights to the platform. The founders of the company are Melissa J MooreAlber Kukukural, Ph.D., Honorary Chief Scientific Officer of Moderna, Ph.D. Associate Director in the Department of Bioinformatics at the UMass Chan School of Medicine and CTO at Via Scientific, Manuel GarberMD, co-director of the Bioinformatics Core at the UMass Chan School of Medicine. Jim CrowleyAnd domestic technology and artificial intelligence entrepreneur and Janet KosloffFounder of healthcare analytics company InCrowd, Inc.
Foundry automates the complex data and analytical work associated with multi-omics research. Featuring a powerful drag-and-drop pipeline and metadata building functionality that eliminates the need to write code, plus a complete process orchestration and customizable analytics, Foundry is a power multiplier for biomedical researchers. Furthermore, the platform ensures that all data and analytics are shareable, reusable, and repeatable. This frees up time and resources for both researchers and bioinformatics experts to focus on generating essential scientific insights and therapeutic breakthroughs.
“We are very pleased to introduce Foundry to the market,” he said. Melissa Moore. “As an academic and CSO at Moderna, I’ve seen firsthand the need for a tool as robust and adaptable as Foundry. Scientists are constantly challenged to keep up with our ability to ask questions and imagine possibilities. Foundry turns ‘processing time’ into ‘scientific’ time, so science teams can focus on Unlocking the fundamental science that yields new insights and breakthroughs.”
“Multi-omics analyzes are very challenging, and we’ve made it our mission to simplify this vital area of research,” he added. Jim CrowleyCEO, Via Scientific. “Scientists should not have to spend their time discussing data, writing code, and coordinating developer reference tasks until they can get to the point where they can start asking their questions. The foundry changes all that as scientists will now spend the time that is intended — interrogating experimental results, shaping insights, and fostering understanding.”
Via Scientific is focused on supporting the analytical needs of biotechnology, pharmaceutical, research institutes, and academic universities, and on further developing the Foundry platform and amplifying its AI capabilities.
About Via Scientific: via Scientific, Inc. , Let’s go Cambridge, Massachusetts– Bioinformatics technology and analytics company. The company was founded in 2022 and went public on February 2023 After a year incognito. The company’s Foundry platform, available on the cloud and as an on-premises solution, radically simplifies multiple analytics at the enterprise level. Via Scientific is growing rapidly and individuals with exceptional engineering, artificial intelligence, and bioinformatics skills can reach the company at firstname.lastname@example.org. Learn more through www.viascientific.com.
About UMass Chan College of Medicine
UMass Chan College of Medicine, one of five campuses on University of Massachusetts system, consisting of TH Chan School from medicine; Morningside Graduate School of Biomedical Sciences; Tan Chingfen Graduate School of Nursing; Commonwealth Medicine, Department of Public Service Counseling; and MassBiologics, the only nonprofit, FDA-approved manufacturer of vaccines, probiotics, and vector gene therapies in the US. United State. UMass Chan’s mission is to enhance the health and wellness of our diverse communities throughout Massachusetts and throughout the world through leadership and innovation in education, research, health care delivery, and public service. In doing so, it has earned a reputation as a global research institution and a leader in primary care education, consistently being ranked in the top 10 percent of primary care medical schools by US news and world report. UMass Chan attracts more than 300 million dollars annually in research funding, placing it among the top 50 medical schools in the country. In 2021, the College of Medicine received an A.D $175 million The donation is from the Morningside Foundation and it has been renamed the UMass Chan College of Medicine.
View original multimedia download content:https://www.prnewswire.com/news-releases/via-scientific-inc-a-new-cambridge-based-technology-and-ai-company-emerges-from-stealth-and-launches-groundbreaking-multi- omics-analytics-platform-301737370.html
Source via Scientific, Inc.